

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 February 2022 (03.02.2022)



(10) International Publication Number
WO 2022/022617 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) A61P 21/00 (2006.01)
A61K 48/00 (2006.01)

(21) International Application Number:
PCT/CN2021/109146

(22) International Filing Date:
29 July 2021 (29.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2020/106200
31 July 2020 (31.07.2020) CN

(71) Applicant: **RACTIGEN THERAPEUTICS** [CN/CN];
Bldg. 18, Rudong Life & Health Industry Park, 888 Zhujiang
Rd., Juegang Avenue, Rudong, Nantong, Jiangsu 226400
(CN).

(72) Inventors: **LI, Longcheng**; Bldg. 18, Rudong Life & Health
Industry Park, 888 Zhujiang Rd., Juegang Avenue, Rudong,
Nantong, Jiangsu 226400 (CN). **KANG, Moorim**; Bldg. 18,
Rudong Life & Health Industry Park, 888 Zhujiang Rd.,
Juegang Avenue, Rudong, Nantong, Jiangsu 226400 (CN).
WU, Jiancheng; Bldg. 18, Rudong Life & Health Industry
Park, 888 Zhujiang Rd., Juegang Avenue, Rudong, Nan-
tong, Jiangsu 226400 (CN).

(74) Agent: **TAHOTA LAW FIRM**; 16/F Palm Spring Interna-
tional Center, 199 Tianfu Avenue Middle, High-Tech Zone,
Chengdu, Sichuan 610041 (CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINATORY TREATMENT OF SMA WITH SARNA AND MRNA MODULATORS




FIG. 12A

(57) Abstract: Provided herein are methods and compositions related to combinations of (a) agents that increase the expression of SMN2 gene or protein, and (b) modulators of SMN2 mRNA splicing or stability that increase the production of functional SMN2 mRNA and SMN protein, and their use in treating SMA and related conditions or diseases. In certain embodiments, the methods relate to using SMN2 saRNA and SMN2 mRNA modulators for diminishing the symptoms of SMA.

[Continued on next page]

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*